Targeting Cardiac Muscle

Time: 8:00 am


  • Cardiac specific delivery of vectors has been achieved using minimally invasive techniques clinically
  • AAV vectors have been used safely in early cardiac gene therapies, but myocardial uptake has been inefficient so far
  • Novel re-engineered AAV vectors are increasing the efficiency of myocardial uptake
  • The scope of cardiac diseases that is being targeted by gene therapy is expanding from monogenic to acquired diseases